Surveillance of Patients With Adenocarcinoma of the Gastroesophageal Junction or Esophagus — SAGE

Adenocarcinoma Esophagus Clinical Trial

Official title:
Study on Outcomes of Active Surveillance Among Invasive Locoregional Adenocarcinoma of Esophagus and Gastroesophageal Junction (GEJ) With Complete Response After Neoadjuvant Combined Chemoradiotherapy

Status Terminated

Clinical Trial Summary

The purpose of this study is to find out more information about patients who have cancer (adenocarcinoma) of the esophagus or gastroesophageal junction (GEJ) who have been treated with chemotherapy and radiation but have not had surgery. The study will follow patients for 5 years to monitor for their cancer and to see how the standard medical care affects the daily life of patients.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02991547
Study type	Observational
Source	The Guthrie Clinic
Contact
Status	Terminated
Phase
Start date	December 2016
Completion date	August 3, 2018

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05067842` - Circulating Tumor DNA (ctDNA) in Locally Advanced Esophageal and Gastroesophageal (GE) Junction Adenocarcinoma
Completed	`NCT02971956` - Pembrolizumab in Refractory Advanced Esophageal Cancer	Phase 2
Recruiting	`NCT04818476` - Outcomes of Endoscopically Resected High-risk Mucosal and Low- and High-risk Submucosal Adenocarcinoma Arising in Barrett's Esophagus
Recruiting	`NCT04028167` - Induction FLOT With CROSS CRT for Esophageal Cancer	Phase 2
Not yet recruiting	`NCT06044311` - Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Esophageal Adenocarcinoma	Phase 2